Cystic Fibrosis and Fragile X Syndrome The Arguments for Antenatal Screening.

Author(s): Jenni Murray, Howard Cuckle

Journal Name: Combinatorial Chemistry & High Throughput Screening
Accelerated Technologies for Biotechnology, Bioassays, Medicinal Chemistry and Natural Products Research

Volume 4 , Issue 3 , 2001

Become EABM
Become Reviewer
Call for Editor


The ultimate public health aim of genetic screening is prevention. This can be achieved by reducing birth prevalence through primary or secondary methods such as pre-conceptional or antenatal screening. Tertiary prevention by neonatal screening is also an option where there is direct unbiased evidence for a substantial improvement in prognosis. In addition to this, the information provided during screening is also of value, enabling individuals to make choices that otherwise would not have been available. Having elucidated the natural histories and genetic defects underlying two common, serious genetic disorders, cystic fibrosis and fragile X syndrome, considerable efforts have been channelled into ascertaining the most efficacious method of prevention. To date there is only indirect evidence to suggest that neonatal screening improves prognosis in cystic fibrosis. Similarly, treatment for fragile X syndrome is limited and therefore early identification of the disorder by neonatal screening is unlikely to improve long term outlook. Thus the focus of this review is on primary and secondary preventive methods.

Keywords: Cystic Fibrosis, Antenatal Screening, genetic defects, CFTR gene, Mathematical models, Financial Costs, musculo-skeletal abnormalities, electrophoretic gel, fragile X syndrome

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2001
Page: [265 - 272]
Pages: 8
DOI: 10.2174/1386207013331093
Price: $65

Article Metrics

PDF: 3